# Cathal Friel says Eurofins Genomics partnership an exciting step in AI data analysis programme

- Link: https://www.directorstalkinterviews.com/cathal-friel-says-eurofins-genomics-partnership-an-exciting-step-in-ai-data-analysis-programme/4121026777
- Published: 2021-10-07T08:39:52+01:00
- Author: Giles

> **Cathal Friel CEO at Open Orphan plc ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l))
> and Chairman of [Poolbeg Pharma plc](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l)(
> [LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l))
> told DirectorsTalk,**
>  “As an exciting step in our AI data analysis programme, [Poolbeg Pharma plc has partnered with leading global biopharma services company](https://www.directorstalkinterviews.com/poolbeg-pharma-rna-sequencing-ahead-of-pioneering-ai-analysis-programme/4121026757),
> Eurofins Genomics to complete RNA sequencing for Poolbeg of Respiratory Syncytial
> Virus (RSV) disease progression samples from human viral challenge studies. This
> deep sequencing work is a key step leading to Poolbeg commencing Artificial Intelligence(
> AI) analysis of its RSV data and will mean that it then has full immunological
> datasets for RSV, as well as influenza, which are ready to use with AI platforms
> to identify drug targets and products for influenza and RSV indications. This 
> data is unique as it covers the full disease cycle and presents significant opportunities
> to unlock insights into these diseases which will magnify the power of the AI 
> analysis. 
> The project with Eurofins is expected to be completed by the end of 2021 and will
> involve next generation RNA sequencing of RSV transcriptomics, or disease progression
> data, which enables the tracking of the biology of immune responses in molecular
> detail during infection. Sequencing of the samples will be tailored for incorporation
> into AI algorithms which will be the first time that human challenge trial immune
> data has been analysed using AI, unlocking unique insights from the rich dataset
> that will enable us to discover new drug candidates for both diseases in a quicker
> and more cost-effective way.”

**Poolbeg Pharma plc** ([LON:POLB](https://www.directorstalkinterviews.com/poolbeg-pharma-plc/polb.l))
is a clinical stage infectious disease pharmaceutical company, with a novel capital
light clinical model which enables them to develop multiple products faster and 
more cost effectively than the traditional biotech model.

Poolbeg aspires to become a “one-stop shop” for big pharma to find Phase II ready
products for development and commercialisation.

Share on:
